Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Prostate Cancer: Update Bulletin [May 2015]

Product Code:
596200383
Release Date:
May 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Prostate Cancer. Topics covered: STRIVE trial impact, PREVAIL trial, the acquisition of Bavarian Nordic's immunotherapy Prostvac (rilimogene galvacirepvec-rilimogene glafolivec) by BMS, Prostvac potential, Phase I NCI sponsored combination study of Prostvac and BMS’ Yervoy (ipilimumab), Phase II STAND trial, the potential of total nucleated cell count as a potential biomarker of response to Provenge, the potential of AstraZeneca’s poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib) as a treatment of PC

Highlights from this event update bulletin

  • What impact will the results of the STRIVE trial, comparing Astellas’/Medivation’s Xtandi (enzalutamide) with bicalutamide, have on current practice?
  • Will the updated analysis of the PREVAIL trial provide any further support for the use of Xtandi and does it influence KOL preference for Xtandi relative to Johnson & Johnson’s Zytiga (abiraterone acetate) in the pre-chemotherapy setting?
  • What are KOL’s views on the acquisition of Bavarian Nordic's immunotherapy Prostvac (rilimogene galvacirepvec-rilimogene glafolivec) by BMS? Do they think Prostvac will live up to expectations?
  • In what treatment settings do KOLs anticipate Prostvac will have the greatest potential?
  • What are KOL’s opinions of the results of the Phase I NCI sponsored combination study of Prostvac and BMS’ Yervoy (ipilimumab)?
  • Will the results of the Phase II STAND trial investigating Valeant’s Provenge (sipuleucel-T) in patients with biochemically-recurrent prostate cancer have any influence on current practice?
  • How do KOLs view the potential of total nucleated cell count as a potential biomarker of response to Provenge?
  • What do KOLs think about the potential of AstraZeneca’s poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib) as a treatment of prostate cancer?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved